September 12, 2026 · 2 min read
BPC-157: what the research actually covers, from rodent studies to the first human pilots
A look at the BPC-157 literature: how much is animal work, what the three small human studies reported, and why reviewers rate the evidence as very low.
BPC-157, short for body protection compound 157, is a synthetic pentadecapeptide, meaning 15 amino acids, that was originally isolated from gastric juice. It turns up constantly in discussions of tendon, muscle and gut repair. The honest way to read that literature is to separate what has been done in animals from what has been done in people, so we do.
The BPC-157 sequence
Sequence: Glycine, Glutamic acid, Proline, Proline, Proline, Glycine, Lysine, Proline, Alanine, Aspartic acid, Aspartic acid, Alanine, Glycine, Leucine, Valine.
- Glycine or proline
- Negatively charged
- Positively charged
- Hydrophobic
- Length
- 15 amino acids
- Average mass
- 1,419.5 Da
- Formula
- C62H98N16O22
Almost all of it is preclinical
A 2025 systematic review in the HSS Journal screened 544 articles dating from 1993 to 2024 and included 36. Thirty-five were preclinical and one was clinical. In those animal models, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries.
The proposed mechanisms overlap. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine points to VEGFR2 signaling and nitric oxide synthesis through the Akt-eNOS axis, which promote angiogenesis and fibroblast activity, plus ERK1/2 signaling and anti-inflammatory effects. The authors note that these effects matter most in poorly vascularized tissue like tendon.
What a 2025 systematic review found
- Preclinical studies35 studies
- Clinical studies1 studies
The human data
A 2026 systematic review in Acta Orthopaedica Belgica searched four databases through 1 June 2026 and found three human studies with 30 participants in total. One was a retrospective study of intra-articular injections for knee pain, one a retrospective pilot of intravesical use for interstitial cystitis, and one a prospective pilot of intravenous safety with two participants.
All three reported symptom improvement in most participants and no treatment-related adverse events. The reviewers judged the methodology poor and the overall certainty of evidence very low, because of serious risk of bias, indirectness and imprecision. Their conclusion was that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials.
Every human study found so far
- Knee pain, intra-articular injectionretrospective16 participants
- Interstitial cystitis, intravesicalretrospective pilot12 participants
- Intravenous safetyprospective pilot2 participants
What this means for a lab reader
Two things stand out. The animal findings are consistent across many experiments, which is why the compound keeps attracting interest. And the step from animal tissue to human benefit has barely been tested, so no one should read the mechanism papers as clinical evidence. A 2026 review in Sports Medicine on the wider peptide gray market makes the same point: favorable results in animals, scarce rigorous human safety data.
One more caution on a related topic. Products sold as blends of BPC-157 with TB-500 have no published studies of the combination that we could find. Any claim about how the two behave together is an extrapolation.
References
- Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J 2025.
- McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025.
- Poolton JT et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026.
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026.
Related research notes
- TB-500 and thymosin beta-4: separating the parent protein from the marketed fragmentThymosin beta-4 has decades of published work. TB-500, sold as a fragment of it, has very little. A research overview of where each stands.
- GHK-Cu: the copper-binding tripeptide and what its skin and wound research showsGHK is a three-amino-acid peptide that binds copper. A research overview of its reported effects on wound healing and skin, and of who produced the evidence.